This was shown by a statistically significant improvement in adapted disease-free survival (+6.4%, HR 0.77) in patients with tumours expressing both oestrogen and progesterone receptors receiving extended treatment, whereas no benefit was observed in patients with tumours expressing only one hormone receptor (p interaction = 0.018). This evidence concerns the gene NR4A1 and neoplasm.